πŸ‡ΊπŸ‡Έ FDA

Intelligence Β· Clinical Pipeline

R&D Pipeline Programs

ClinicalTrials.gov programs linked to pharma sponsors β€” phase, modality, and trial IDs for BD and competitive intelligence.

Programs indexed
20,548
Companies
1,769
Drugs tracked
4,797

Quick answer

NovaPharmaNews tracks 20,548 pharmaceutical R&D pipeline programs sourced from ClinicalTrials.gov, linked to sponsor companies. Each profile includes development phase, modality, trial status, NCT identifiers, and indication text β€” searchable for business development and competitive intelligence.

114 results for β€œGT” Clear

  1. "myk-461 capsules, placebo is a solid oral dosage form in size 2 gelatin capsules each containing 120 mg of an excipient blend. it is intended as a placebo to match myk-461 capsules of all active strengths", Mavacamten, Mavacamten, Mavacamten, Mavacamten, Mavacamten

    Bristol-Myers Squibb Australia Pty Ltd

    Symptomatic Obstructive Hypertrophic Cardiomyopathy

    phase 3 small molecule active

    1 trial

  2. 0.9% (w/v) sodium chloride with 5 mM phosphate buffered solution, Zilebesiran

    Alnylam Netherlands B.V.

    High cardiovascular risk, Established cardiovascular disease, Hypertension

    phase 3 small molecule active

    1 trial

  3. ABIRATERONE ACETATE, DAROLUTAMIDE, Locametz 25 micrograms kit for radiopharmaceutical preparation, APALUTAMIDE, Pluvicto 1 000 MBq/mL solution for injection/infusion, ENZALUTAMIDE

    Ningbo Cancer Hospital

    Novo metastatic hormone-sensitive prostate cancer (mHSPC) patients having a serum PSA level of β‰₯ 0.2 ng/mL at 6 to 8 months after systemic treatment initiation for mHSPC (i.e. poor responders) in the absence of evidence of cancer progression (including a rising PSA level)

    phase 3 small molecule active

    1 trial

  4. ACR16

    Teva Pharma GmbH

    Huntington's Disease

    phase 3 small molecule completed

    1 trial

  5. AZACITIDINE, Lisaftoclax, Dummy APG-2575 oral tablets, matching APG-2575 oral tablets. strength: 200 mg/tablet., AZACITIDINE

    Lacuna Pharma Pty Ltd

    Acute myeloid leukemia

    phase 3 small molecule active

    1 trial

  6. B/F/TAF (Adult Strength)

    Gilead Sciences Ireland UC

    HIV-1 Infection

    phase 3 small molecule active

    1 trial

  7. BAY 1841788, TRIPTORELIN

    Ningbo Cancer Hospital

    Patients with localised prostate cancer and high-risk features of relapse (minimum 2 high-risk criteria from National Comprehensive Cancer Network (NCCN) classification)1 and with no detectable metastasis, including no evidence of pelvic lymph node metastasis on next-generation imaging (PSMA PET/CT).

    phase 3 small molecule active

    1 trial

  8. CGT9486 plus sunitinib

    Cogent Biosciences

    Advanced Gastrointestinal Stromal Tumors

    phase 3 small molecule active

    1 trial

  9. Chestnut Bloomington Outpatient (CBOP)

    BRIGHT MINDS BIOSCIENCES INC.

    Substance Abuse

    phase 3 other completed

    1 trial

  10. Decitabine, Homoharringtonine, Aclarubicin, Cytarabine and G-CSF

    Hospital Authority, Hong Kong

    Acute Myeloid Leukemia

    phase 3 small molecule active

    1 trial

  11. Deutetrabenazine

    Teva Pharma GmbH

    Huntington Disease

    phase 3 small molecule active

    1 trial

  12. GTX-102

    Ultragenyx UK Limited

    Angelman Syndrome

    phase 3 small molecule active

    4 trials

  13. GTX-102, GTX/UX Diluent and Flush Solution

    Lacuna Pharma Pty Ltd

    Angelman Syndrome

    phase 3 small molecule active

    1 trial

  14. GTX-104

    Grace Therapeutics

    Aneurysmal Subarachnoid Hemorrhage (aSAH)

    phase 3 small molecule active

    1 trial

  15. GTX/UX Diluent and Flush Solution, GTX-102, ELLIOTTS B SOLUTION (buffered intrathecal electrolyte/dextrose injection)

    Lacuna Pharma Pty Ltd

    Angelman Syndrome

    phase 3 small molecule active

    1 trial

  16. Genotype-guided dosingTaiwan algorithm for warfarin

    Xiyuan Hospital of China Academy of Chinese Medical Sciences

    Stroke

    phase 3 gene therapy completed

    1 trial

  17. Idursulfase (idursulfase-IT [HGT-2310])

    Takeda

    Hunter Syndrome and Cognitive Impairment

    phase 3 small molecule active

    1 trial

  18. LEUPRORELIN ACETATE, BAY 1841788, NUBEQA 300 mg film-coated tablets, TRIPTORELIN, DEGARELIX, GOSERELIN

    Ningbo Cancer Hospital

    Castrate-resistant prostate cancer with oligometastases on functional imaging (PSMA or choline/fluciclovine-positron-emission tomography).

    phase 3 small molecule active

    1 trial

  19. Pegtibatinase

    Travere Therapeutics

    Homocystinuria

    phase 3 small molecule active

    3 trials

  20. Pegtibatinase, 0.9 % sodium chloride saline solution (NaCL)

    Travere Therapeutics

    Classical Homocystinuria

    phase 3 small molecule active

    1 trial

  21. Placebo (inhalation powder capsules) containing 1 of 3 dosage strengths of TPIP (80 ΞΌg, 160 ΞΌg, or 320 ΞΌg), TREPROSTINIL PALMITIL INHALATION POWDER

    Insmed Limited

    Pulmonary Hypertension Associated with Interstitial Lung Disease

    phase 3 small molecule active

    1 trial

  22. Placebo (inhalation powder capsules) containing 1 of 4 dosage strengths of TPIP (80 ΞΌg, 160 ΞΌg, or 320 ΞΌg or 640 Β΅g ), TREPROSTINIL PALMITIL INHALATION POWDER, TREPROSTINIL PALMITIL INHALATION POWDER, TREPROSTINIL PALMITIL INHALATION POWDER, TREPROSTINIL PALMITIL INHALATION POWDER

    Insmed Limited

    Pulmonary Hypertension Associated with Interstitial Lung Disease

    phase 3 small molecule active

    1 trial

  23. Placebo of BELAPECTIN, BELAPECTIN

    GALECTIN THERAPEUTICS INC

    Esophageal Varices in NASH Cirrhosis

    phase 3 small molecule active

    1 trial

  24. SAGE-718

    SUPERNUS PHARMACEUTICALS, INC.

    Huntington's Disease

    phase 3 small molecule terminated

    2 trials

Frequently asked questions

What is the NovaPharmaNews pipeline directory?

It is a searchable index of 20,548 clinical development programs grouped by sponsor company, with phase (Phase 1–3), modality, trial status, and linked NCT IDs from ClinicalTrials.gov.

Where does pipeline data come from?

Program records are derived from ClinicalTrials.gov and linked to NovaPharmaNews company profiles. Trial status and phase reflect registry data at last sync β€” verify on ClinicalTrials.gov before investment or partnering decisions. See our data sources page for attribution.

How do I find pipeline programs by company or phase?

Use the search box to match program name, indication, company name, or slug. Results are ordered with late-stage (Phase 3) programs first. Open any row to view the full program profile under its sponsor company.

Data attribution and licensing: Data sources